Celltrion Is Latest To Snag A US Stelara Rival

Steqeyma Becomes Seventh FDA-Approved Ustekinumab Biosimilar

 
• By Dave Wallace
  
Celltrion’s Steqeyma is the seventh ustekinumab biosimilar lining up for launch in the US (Shutterstock)

More from Biosimilars

More from Generics Bulletin